Biphasic insulin aspart 30 treatment in patients with type 2 diabetes poorly controlled on prior diabetes treatment: results from the PRESENT study

References

• Mayfield JA, White RD. Insulin therapy for type 2 diabetes: rescue, augmentation, and replacement of beta-cell function. Am Fam Physician 2004;70:489–500 [published correction appears in Am Fam Physician 2004;70: 2079–80]
   Google Scholar
• IDF Clinical Guidelines Task Force. Global guideline for type 2 diabetes. 1st edn. Brussels: International Diabetes Federation, 2005
   Google Scholar
• AACE Diabetes Mellitus Clinical Practice Guidelines Task Force. AACE medical guidelines for clinical practice for the management of diabetes mellitus. Endocr Pract 2007;13 (Suppl 1):3–68
   Google Scholar
• Raccah D, Bretzel RG, Owens D, Riddle M. When basal insulin therapy in type 2 diabetes mellitus is not enough – what next? Diabetes Metab Res Rev 2007;23:257–64
   PubMed Web of Science ®Google Scholar
• Bell DS, Ovalle F. Long-term glycaemic efficacy and weight changes associated with thiazolidinediones when added at an advanced stage of type 2 diabetes. Diabetes Obes Metab 2006;8:110–5
   PubMed Web of Science ®Google Scholar
• Dickinson PJ, Dornhorst A, Frost GS. A retrospective case-control study of initiating insulin therapy in type 2 diabetes. Pract Diab Int 2002;19: 67–70
   Google Scholar
• de Sonnaville JJJ, Snoek FJ, Colly LP, et al. Well-being and symptoms in relation to insulin therapy in type 2 diabetes. Diabetes Care 1998;21:919–24
   PubMed Web of Science ®Google Scholar
• Wright A, Burden ACF, Paisey RB, et al.; for the UK Prospective Diabetes Study Group. Sulfonylurea inadequacy: efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the U.K. Prospective Diabetes Study (UKPDS 57). Diabetes Care 2002;25: 330–6
   Google Scholar
• Turner RC, Cull CA, Frighi V, Holman RR; for the UK Prospective Diabetes Study group. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). JAMA 1999;281: 2005–12
   Google Scholar
• Halimi S, Raskin P, Liebl A, et al. Efficacy of biphasic insulin aspart in patients with type 2 diabetes. Clin Ther 2005; 27(Suppl B):S57–75
   Google Scholar
• Shestakova M, Sharma SK, Almustafa A, et al. Transferring type 2 diabetes patients from biphasic human insulin to biphasic insulin aspart 30: experiences from the PRESENT study. [Epub ahead of print 13th Nov 2007]
   Google Scholar
• Abrahamian H, Ludvik B, Schernthaner G, et al. Improvement of glucose tolerance in type 2 diabetic patients: traditional vs. modern insulin regimens (results from the Austrian Biaspart Study). Horm Metab Res 2005;37:684–9
   PubMed Web of Science ®Google Scholar
• Garber AJ, Wahlen J, Wahl T, et al. Attainment of glycaemic goals in type 2 diabetes with once-, twice-, or thrice-daily dosing with biphasic insulin aspart 70/30 (the 1–2–3 study). Diabetes Obes Metab 2006;8:58–66
   PubMed Web of Science ®Google Scholar
• Raskin P, Allen E, Hollander P, et al.; for the INITIATE study group. Initiating insulin therapy in type 2 diabetes: a comparison of biphasic and basal insulin analog. Diabetes Care 2005;28: 260–5
   Google Scholar
• Schwartz S, Sievers R, Strange P, et al.; for the INS-2061 study team. Insulin 70/30 mix plus metformin versus triple oral therapy in the treatment of type 2 diabetes after failure of two oral drugs: efficacy, safety, and cost analysis. Diabetes Care 2003;26: 2238–43
   Google Scholar
• Kilo C, Mezitis N, Jain R, et al. Starting patients with type 2 diabetes on insulin therapy using once-daily injections of biphasic aspart 70/30, biphasic human insulin 70/30, or NPH insulin in combination with metformin. J Diabetes Complications 2003;17:307–13
   PubMed Web of Science ®Google Scholar
• Kvapil M, Swatko A, Hilberg C, Shestakova M. Biphasic insulin aspart 30 plus metformin: an effective combination in type 2 diabetes. Diabetes Obes Metab 2006;8:39–48
   PubMed Web of Science ®Google Scholar
• Raz I, Mouritzen U, Vaz J, et al. Addition of biphasic insulin aspart 30 to rosiglitazone in type 2 diabetes mellitus that is poorly controlled with glibenclamide monotherapy. Clin Ther 2003;25:3109–23
   PubMed Web of Science ®Google Scholar
• Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2006;29:1963–72
   PubMed Web of Science ®Google Scholar
• DCCT Research Group. The association between glycemic exposure and long-term diabetic complications in the Diabetes Control and Complications Trial. Diabetes 1995;44:968–83
   PubMed Web of Science ®Google Scholar
• Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000;321:405–12
   PubMed Web of Science ®Google Scholar
• Davidson J, Vexiau P, Cucinotta D, et al. Biphasic insulin aspart 30: literature review of adverse events associated with treatment. Clin Ther 2005;27(Supp B): S75–88
   Google Scholar
• Skovlund SE, Peyrot M; on behalf of the DAWN International Advisory Panel. The Diabetes Attitudes, Wishes, and Needs (DAWN) Program: a new approach to improving outcomes of diabetes care. Diabetes Spectrum 2005;18:136–42
   Google Scholar
• Raccah D, Hanaire-Broutin H, Sert-Langeron C, et al. Insulin initiation in type 2 diabetic patients admitted in hospital in France and follow-up at 1 year: the IDAHO 2 study. Diabetes Metab 2006;32:244–50
   PubMed Web of Science ®Google Scholar